Pharmacokinetisc-pharmacodynamics relationships of imatinib (Glivec®);Pharmacocinétique (PK) et pharmacodynamie (PD) de l'imatinib (Glivec®)

Therapie

Volumn 62, Issue 2, 2007, Pages 87-90

  Delbaldo, Catherine ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Imatinib; Pharmacodynamics; Pharmacokinetics

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; CYTOCHROME P450; IMATINIB; OROSOMUCOID; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANEMIA; ANOREXIA; AREA UNDER THE CURVE; CONFERENCE PAPER; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MYALGIA; NAUSEA AND VOMITING; PRIORITY JOURNAL; RASH; ARTICLE; DRUG TOLERANCE; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG TOLERANCE; HUMANS; METABOLIC CLEARANCE RATE; NEOPLASMS; OXIDATION-REDUCTION; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 34548626372     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007021     Document Type: Conference Paper

References (24)

1. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000; 59 (4): 753-67
2. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19 (56): 6550-65
3. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20 (6): 1692-703
4. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-32
5. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45
6. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80
7. Lasota J, Jasinski M, Salrlomo-Rikala M, et al. Mutaion in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal tumors and do not occur in leomyomas and leomyosarcomas. Am J Pathol 1999; 154: 53-60
8. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukemia: results of a phase III study. Br J Clin Pharmacol 2005; 60: 35-44
9. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9: 625-32
10. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4: 224-32
11. Piafsky KM, Borga O. Plasma protein binding of basic drugs. Importance of alpha 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther 1977; 22: 545-49
12. Larghero J, Leguay T, Mourah S, et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 2003; 66(10): 1907-13
13. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-42
14. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55: 379-86
15. Novartis Pharma Stein AG. Gleevec® (imatinib mesylate): prescribing information [online]. Available from URL: http://www.gleevec.com/info/page/ prescribinginfo
16. Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76: 323-29
17. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34
18. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST, Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 2004; 22: 9005
19. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Lancet 2001; 358 (9291): 1421-3
20. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472-80
21. Heinrich C, Corless CL, Von Mehren M, et al. PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 2003; 22: 3274
22. Theou N, Tabone S, Saffroy R, et al. High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors. Biochim Biophys Acta 2004; 1688 (3): 250-6
23. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42 (8): 1093-103
24. Fletcher A, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2003; 22: 3275